Cash boost for UK bioprocessing

Article

Pharmaceutical Technology Europe

The private industry has been urged to join a public sector commitment fund in the UK to advance manufacturing R&D in bioprocessing, following the investment of approximately £9 million from two UK research councils.

The private industry has been urged to join a public sector commitment fund in the UK to advance manufacturing R&D in bioprocessing, following the investment of approximately £9 million from two UK research councils.

The amount, provided by the UK's Biotechnology and Biological Sciences Research Council (BBSRC) and the Engineering and Physical Sciences Research Council (EPSRC), has been committed to the second phase of the public–private partnership Bioprocessing Research Industry Club: BRIC 2. The first phase of BRIC established a coherent bioprocessing community in the UK; the second phase aims to increase the numbers of trained bioprocessing professionals.

"The BRIC programme not only provides funds for projects that are relevant for all companies developing and manufacturing biological medicines, but also has produced a stream of researchers with the skills that are much needed by the UK bioprocessing sector," Mark Bustard, Head of bioprocessUK — which strongly supports the investment —said in a press statement. "This is a unique activity within the UK that we aim to build on to increase competitiveness and innovation in the development of biological medicines."

In a separate press statement issued by the BBSRC, Celia Caulcott, Director for Innovation and Skills, said: "We have been running the first phase of the partnership since 2005 when we committed to investing a combined total of £14 million. I am proud to say we have 17 bioprocessing companies in the club. BRIC 2 will build on early successes, but needs the commitment of both existing and new companies in the sector."

www.bbsrc.ac.uk

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content